drugset / Trial / NCT01290328
Study of Epoetin Alfa to Treat Anemia After Kidney Transplantation
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary purpose of this study is to determine the effect of Epoetin Alfa (Procrit) on the change in hemoglobin (red blood cell count) in anemic kidney transplant recipients. The investigators hypothesize that epoetin alfa will raise hemoglobin.
Timeline
- Start
- 2011-02
- Primary completion
- 2014-03
- Completion
- 2014-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | epoetin alfa | Protein / enzyme biologic | 150 iu/kg | — |